Distribution of Psychotropic Drugs Into Lipoproteins

Trond T. Serkland, MD,* Jan Schjøtt, PhD,**† Jon A. Berg, MD,* Lars Herfindal, PhD,‡
Bettina Riedel, PhD,**† and Silje Skrede, PhD*†

Aim: The aim of this pilot study was to investigate whether psychotropic drugs frequently analyzed in a routine therapeutic drug monitoring laboratory bind to low-density lipoproteins/very-low-density lipoproteins (LDL/VLDL) in human serum.

Methods: Drug concentrations in 20 serum sample pools containing one psychotropic drug each, and in the LDL/VLDL fractions extracted from the same samples, were measured by triple quadrupole liquid chromatography tandem mass spectrometry. The membrane permeability of the drugs was measured using a Parallel Artificial Membrane Permeability Assay.

Results: Of the 20 antidepressants, antipsychotics, and antiepileptics examined, 7 drugs were detected in both the pooled serum samples and in the LDL/VLDL fraction. Binding of drugs to LDL/VLDL significantly correlated with high octanol: water partition coefficient (logP), high degree of protein binding, and a low polar surface area. The drugs found in LDL/VLDL, with the exception of aripiprazole, were also characterized by high or intermediate membrane permeability.

Conclusions: The present results indicate that psychotropic drugs with certain characteristics bind to LDL/VLDL in blood. This further implies that lipoproteins could play an important role in drug transport.

Key Words: lipoproteins, psychotropic drugs, TDM, membrane permeability

(Ther Drug Monit 2019;41:766–771)

INTRODUCTION

In pharmacology, the currently accepted dogma is that drugs are transported in the blood either bound to proteins or in an unbound form, and that only the latter is able to exert the desired effect by, for instance, penetrating the endothelium to reach the target cells. In therapeutic drug monitoring (TDM), the total amount of drug in blood, that is, the sum of protein-bound and unbound substance, is most commonly measured.

During the past decades, scattered studies have indicated that psychotropic drugs may not only bind to the traditional drug transport proteins (albumin, α1-acid glycoprotein), but also to lipoproteins.1–11 Recent preclinical experiments showed that antiplatelet and antiarrhythmic agents can bind to low-density lipoproteins/very-low-density lipoproteins (LDL/VLDL), which influence the pharmacokinetics of these drugs, partly because of LDL receptor-mediated uptake of lipoprotein-bound drugs into hepatocytes.12 This was described as a fundamental new concept in pharmacokinetics.

Psychotropic drugs are frequently prescribed because of a high prevalence of psychiatric diseases, but are associated with interactions and metabolic adverse effects (eg, weight gain and cardiovascular disease).13,14 Furthermore, several antipsychotic agents, such as quetiapine, olanzapine, and clozapine, have been shown to increase the risk of hyperlipidemia.15 A potential association with lipoproteins is therefore of particular interest regarding psychotropic drugs. In theory, such drugs can potentiate their own delivery to target tissues through their lipogenic adverse effects.

The main physiological role of lipoproteins is to transport lipids such as cholesterol and triglycerides through the hydrophilic environment of the circulatory system. Lipoproteins are classified based on their density, from the lowest density, the chylomicrons, to VLDL, LDL, and finally high density lipoproteins. In addition to being the main transporters of lipids in the blood, lipoproteins can also carry certain lipophilic compounds such as fat-soluble vitamins and xenobiotics like endocrine-disrupting chemicals.16–18

In this pilot study, we selected a group of psychotropic drugs frequently analyzed in our routine TDM laboratory to examine distribution to LDL/VLDL. Drug concentrations were measured in pooled serum samples, and in isolated LDL/VLDL fractions from the same samples. To further investigate possible mechanisms for drug-lipoprotein association, we measured whether the drugs could cross biological membranes using a Parallel Artificial Membrane Permeability Assay (PAMPA) kit. The results were correlated with the physicochemical properties of the drugs to reveal potential characteristics of molecules found in the lipoprotein fraction.

MATERIALS AND METHODS

LDL/VLDL Isolation

By the use of our own in-house data on drugs, which are monitored by TDM, we identified 20 of the most frequently analyzed drugs (antiepileptics, antipsychotics and antidepressants). TDM serum samples no longer eligible for
Parallel Artificial Membrane Permeability Assay

Compound solutions were prepared by diluting 20 mM of drug stock solutions [in dimethyl sulfoxide (DMSO)] in phosphate-buffered saline (pH 7.4) to a final concentration of 50 μM. Passive diffusion across an artificial membrane was measured using the PAMPA kit from Corning Genetest (Discovery Labware, Inc., Bedford, MA), according to the manufacturer’s instructions. In summary, a 96-well filter plate, precoated with lipids, was used as the permeation acceptor and a matching 96-well receiver plate was used as the permeation donor. To confirm the integrity of the membrane separating the donor wells from the acceptor wells, we used doxorubicin as an impermeable control substance, and chlorpromazine as a highly permeable substance. After 5 hours of incubation, the concentrations in the donor and acceptor wells were measured and the membrane permeability was calculated. The membrane permeability is measured in centimeters per second and presented as logarithmic values (Log Pₑ). Based on this parameter, the following categorization of permeability has been suggested: High (≥−5.33), intermediate (≥−5.66 and <−5.33), low (≥−6.14 and <−5.66) and impermeable (≥−6.14). The pH value in the donor wells was measured using a photometric method on a Beckman Coulter AU680 (Bekman Coulter, Brea, CA).

Calculations

All physicochemical parameters [octanol:water partition coefficient (logP), polar surface area (PSA), protein binding (PB)], and logarithmic acid dissociation constant (pKa) were extracted from Drug Bank. Because of lack of data, the PB of levomepromazine was assumed to be the same as alimemazine, based on structural similarities. The compatibility factor (CF), as presented in a paper regarding gel separator tubes, for each drug was calculated using the following formula:

$$CF = \left(\frac{(\log P)^2 \times PB}{PSA}\right)$$

The ratio between the concentration measured in the LDL/VLDL fractions and the concentration measured in the initial serum pools (L/S-ratio) were also estimated for each drug.

Regarding the PAMPA results, the permeability (cm/s) of the compounds were calculated using the following formula:

$$P_e = \frac{-\ln[1 - C_A(t)/C_{eq}]}{A \times (1/V_D + 1/V_A) \times t}$$

where A = filter area (0.3 cm²), V_D = donor well volume (0.3 mL), V_A = acceptor well volume (0.2 mL), t = incubation time (seconds), C_A(t) = compound concentration in acceptor well at time t, C_eq = compound concentration in donor well at time t, and

$$C_{eq} = \frac{|C_D(t) \times V_D + C_A(t) \times V_A|}{(V_D + V_A)}$$

Statistics

All statistical analyses were conducted using IBM SPSS statistics for Apple ver. 25 (IBM, Armonk, NY). A P value <0.05 was required to achieve a statistical significance. To investigate whether logP, PB, PSA, or CF was correlated with the presence of drugs in lipoproteins or not, we performed a nonparametric Mann–Whitney U test, with the null hypotheses that the distribution of logP, PB, PSA, and CF of the drugs included in the study was equal in the drugs found in lipoproteins as for those not present in lipoproteins. To investigate the impact the 3 independent parameters have on lipoprotein association, a ternary plot was created using the SigmaPlot software ver. 9.0 (Systat Software, San Jose, CA).

Ethics

The study was performed using disposable, pooled TDM samples, with no possibility of identifying the individual patients.

RESULTS AND DISCUSSION

Successful purification of LDL/VLDL was confirmed by measurements of LDL and albumin in randomly selected samples after LDL/VLDL fractionation. In these LDL/VLDL fractions, high concentrations of LDL (14.2–17.8 mmol/L)
and albumin concentrations below the detection limit (2 g/L) were found (data not shown).

Of the 20 antidepressants, antipsychotics, and antiepileptics examined, 7 drugs were detected both in the pooled serum samples and in the LDL/VLDL fraction extracted from the same samples (Table 1). Four were antidepressants (sertraline, amitriptyline, fluoxetine, and paroxetine) and 3 were antipsychotics (levomepromazine, aripiprazole, and clozapine). Mean concentrations in the serum pools and in the LDL/VLDL fractions, respectively, were (nmol/L): sertraline: 281/428, amitriptyline: 245/30, fluoxetine: 487/193, paroxetine: 168/24, levomepromazine: 10/3, aripiprazole: 245/30, and clozapine: 2342/94. None of the antiepileptic agents were present in LDL/VLDL.

The concentrations in the LDL/VLDL fractions suggest that for some agents, a significant proportion may be associated with LDL/VLDL particles in vivo. Interestingly, sertraline was found in a higher concentration in the LDL/VLDL fractions than in the respective serum pools. For all 7 substances detected in the LDL/VLDL fractions, we observed a tendency toward a higher logP with higher ratios between the concentrations in LDL/VLDL and serum (L/S ratio, Table 1).

By further examining the influence of the drugs’ physicochemical properties, we found that association of drugs with LDL/VLDL significantly correlated with a high logP value, high degree of PB, and low PSA (Figs. 1A–D, Mann–Whitney U test: P < 0.001). We therefore plotted the values of the 3 physicochemical parameters of each drug analyzed into a ternary plot to check whether the drugs associated with the lipoproteins had similar properties, that is, whether the contribution of each physicochemical parameter was similar for each drug (Fig. 1E). In this plot, we noticed a clear cluster of drugs associated with LDL/VLDL, where the strongest determining factor was high logP and low PSA. The impact of PB was less evident. These findings connect with an intuitive assumption: That substances with low polarity and high fat solubility are prone to associate with lipoproteins when present in blood. The drugs not associated with the lipoproteins were scattered throughout the plot and no common characteristic could be found for these. Haloperidol, which shares the criteria of the drugs detected in the LDL/VLDL fraction, was not detected in lipoproteins. However, the reference range for haloperidol is low compared with the other psychotropic drugs. It may therefore be that the drug is below the detection limit in lipoproteins, because of the low total concentration in the blood.

The CF (Equation 1) has been suggested as an indicator for determining whether a drug would bind to the lipophilic gel in gel separator tubes. According to our results, the CF also correlated with high lipoprotein association as expected, because the CF is a function of the 3 physicochemical

| TABLE 1. Physicochemical Properties of Antidepressants, Antipsychotics, and Antiepileptics, and Distribution to LDL/VLDL in Human Serum |
|-----------------|---|---|---|---|---|---|---|
| **Antidepressants** | **LogP** | **PB** | **PSA** | **CF** | **Found in LDL** | **L/S-Ratio** | **LogP e** | **Permeation Category** |
| Sertraline | 5.10 | 98 | 12.0 | 212.4 | X | 1.51 | −5.51 | Intermediate |
| Amitriptyline | 4.92 | 97 | 3.2 | 733.8 | X | 0.17 | −5.24 | High |
| Fluoxetine | 4.05 | 95 | 21.3 | 74.2 | X | 0.40 | −5.26 | High |
| Paroxetine | 3.60 | 95 | 39.7 | 30.8 | X | 0.14 | −5.30 | High |
| Escitalopram | 3.50 | 56 | 36.2 | 18.9 | | | | |
| Venlafaxine | 3.20 | 30 | 32.7 | 9.4 | | | | |
| Mirtazapine | 2.90 | 85 | 19.4 | 3.9 | | | | |
| **Antipsychotics** | | | | | | | | |
| Levomepromazine | 4.70 | 90 | 15.7 | 124.3 | X | 0.32 | −5.40 | Intermediate |
| Aripiprazole | 4.50 | 99 | 44.8 | 44.6 | X | 0.13 | −8.83 | Impermeable |
| Haloperidol | 4.30 | 92 | 40.5 | 42.0 | | | | |
| Clozapine | 3.20 | 95 | 30.9 | 31.4 | X | 0.06 | −5.24 | High |
| Quetiapine | 2.80 | 83 | 48.3 | 13.5 | | | | |
| Risperidone | 2.50 | 88 | 61.9 | 8.9 | | | | |
| Olanzapine | 2.00 | 93 | 30.9 | 12.0 | | | | |
| Paliperidone | 1.80 | 74 | 82.2 | 2.9 | | | | |
| Aminosulpride | 1.06 | 17 | 101.7 | 0.2 | | | | |
| **Antiepileptics** | | | | | | | | |
| Valproic acid | 2.75 | 90 | 37.3 | 18.2 | | | | |
| Lamotrigine | 2.50 | 55 | 90.7 | 3.8 | | | | |
| Carbamazepine | 2.45 | 76 | 46.3 | 9.9 | | | | |
| Levetiracetam | −0.60 | 10 | 63.4 | 0 | | | | |

See Methods section for information of how the different parameters were collected and calculated.

CF (compatibility factor) = [(logP)² × PB] / PSA; logP, partition coefficient; L/S ratio (lipoprotein–drug ratio), drug concentration in LDL-VLDL/drug concentration in serum (mean value, amitriptyline: n = 2, fluoxetine: n = 2, paroxetine: n = 3, sertraline: n = 2, aripiprazole: n = 3, clozapine: n = 2, levomepromazine: n = 3); LogPe = the logarithmic value of the membrane permeability (cm/s) (mean value: clozapine: n = 3, amitriptyline: n = 3, paroxetine: n = 3, levomepromazine: n = 3, aripiprazole: n = 3, fluoxetine: n = 2, sertraline: n = 2); PB, protein binding in percent.
parameters mentioned above. However, it is noteworthy that in the equation for CF, the value of logP is squared. As a consequence, a positive and negative logP will yield the same value, contributing equally to the CF value. This factor can thus only be used if all the drugs to be compared have a logP value above zero. As seen from Table 1, one of our drugs had a negative logP (levetiracetam; logP = -0.60), and the CF may not be a fully adequate predictor in determining drug association to lipoproteins.

According to the classification detailed in the “Materials and Methods” section, PAMPA results demonstrated that 6 of the 7 drugs found in LDL/VLDL had a high or intermediate membrane permeability, whereas aripiprazole came out as impermeable in our study (Table 1). One might suspect that aripiprazole did not permeate the membrane, because it was present in an ionized form. We therefore measured the pH value in the donor wells, which was close to 7.4 in all wells (data not shown). This is close to the pKa for aripiprazole (7.46). However, the pKa value of quetiapine (7.06) and clozapine (7.5) also lies close to this value, and both of these substances were found to be highly permeable. The pH value in the donor wells therefore cannot explain the impermeability of aripiprazole. Another explanation could be that aripiprazole is trapped in the membrane, hinting that its association with lipoprotein is in the phospholipid layer, rather than the triglyceride and cholesterol-containing core. This could not be determined by means of the PAMPA assay.
In a previous report, the permeability of 4 of the drugs included in the present study (clozapine, fluoxetine, paroxetine, and amitriptyline) was examined. Although the exact LogP\textsubscript{e} values calculated by us deviate somewhat from these findings, all drugs fell into the same suggested permeation categories (high or intermediate).

Regarding the limitations, the samples used in this study had been stored for 7 days at 4°C before LDL/VLDL fractionation and drug analysis. This may have influenced how drugs distribute to LDL/VLDL. Furthermore, we have no information about the patients’ medical history or the sampling circumstances. However, the serum pool drug concentrations were all within the respective reference ranges common in standardized TDM. Furthermore, to be able to compare 20 drugs, the number of biological replicates was limited to one. In future experiments, the number of parallels should be significantly increased to strengthen the basis of the conclusions.

CONCLUSIONS

In this pilot study, we showed that several psychotropic drugs are associated with LDL/VLDL isolated from human serum. Our results support the model suggested by Yamamoto et al,\textsuperscript{12} with total measured drug concentrations representing the sum of not only free and protein-bound drug, but the sum of free, protein-bound, and lipoprotein-bound drug.

The drugs found in LDL/VLDL were all characterized by a high logP value, high degree of PB, and low PSA. With the exception of aripiprazole, they were also characterized by high or intermediate membrane permeability.

The association of drugs with lipoproteins may have wide-ranging consequences. It has been suggested that lipoprotein-associated drug transport should be distinguished from protein-bound transport because of the ability of lipoproteins to be transferred into tissues and cells through receptor-mediated endocytosis.\textsuperscript{12} Our study supports this concept.

If drugs follow lipoproteins into relevant tissues, they may reach a higher tissue concentration than assumed based on the size of the free fraction in blood, with implications for effect and side effect profiles alike. This implies that the concentration of LDL and VLDL in blood could be of importance for the tissue concentration of drugs. Furthermore, coadministration of statins, shown to increase the expression of LDL receptors,\textsuperscript{24} may potentially influence the biodistribution and effect of a drug associated to lipoproteins.

Further research is needed to evaluate whether distribution into VLDL/LDL affects the cellular uptake of psychotropic drugs, and which pharmacological and/or clinical consequences this may have. Importantly, revealing the details of distribution of lipophilic drugs to lipoproteins may also contribute to the development of artificial lipoproteins for targeted delivery of pharmacological agents.\textsuperscript{25,26}

ACKNOWLEDGMENTS

The authors would like to thank the medical laboratory and scientific staff at the Department of Medical Biochemistry and Pharmacology at Haukeland University Hospital and Centre for Pharmacy at the University of Bergen for excellent technical contributions; In particular Kjell Ove Fossan, Kjersti Carstensen, and Reidun Åsøy.

REFERENCES

1. Krag CL, Strisower EH, Green HR, et al. Reserpine and human serum lepoproteins. Int Rec Med Gen Pract Clin. 1958;17:655–660.
2. Verbeek RK, Cardinal JA, Hill AG, et al. Binding of phenothiazine neuroleptics to plasma proteins. Biochem Pharmacol. 1983;32:2565–2570.
3. Tamura A, Kawase F, Sato T, et al. Binding of chlorpromazine, phenytoin and aspirin to the erythrocytes and lipoproteins in whole human blood. J Pharm Pharmacol. 1987;39:740–742.
4. Van Gent CM, Sandberg LB, Boucek RJ. Haloperidol administration to rats during pregnancy induces permanent alterations in serum lipoprotein patterns of progeny. J Clin Psychopharmacol. 1991;11:113–115.
5. Procyshyn RM, Kennedy NB, Marriage S, et al. Plasma protein and lipoprotein distribution of clozapine. Am J Psychiatry. 2001;158:949–951.
6. Pande S, Procyshyn RM, Nazerali M, et al. Do triglycerides modulate the effectiveness of clozapine? Int Clin Psychopharmacol. 2002;17:197–199.
7. Procyshyn RM, Tsai G, Wasan KM. The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidol. Eur Neuropsychopharmacol. 2003;13:33–37.
8. Procyshyn RM, Ho T, Wasan KM. Competitive displacement of clozapine from plasma proteins in normolipidemic and hyperlipidemic plasma samples: clinical implications. Drug Dev Ind Pharm. 2005;31:331–337.
9. Procyshyn RM, Ho T, Wasan KM. The effects of competitive displacement on haloperidol’s plasma distribution in normolipidemic and hyperlipidemic plasma. Drug Dev Ind Pharm. 2005;31:901–905.
10. Shahnaz G, Hartl M, Barthelmes J, et al. Uptake of phenothiazines by the harvested chylomicrons ex vivo model: influence of self-nanoemulsifying formulation design Eur J Pharm Biopharm. 2011;79:171–180.
11. Adachi H, Yanai H, Hirowatari Y. The underlying mechanisms for olanzapine-induced hypertriglyceridemia. J Clin Med Res. 2012;4:206–208.
12. Yamamoto H, Takada T, Yamanashi Y, et al. VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body. Sci Rep. 2017;7:633.
13. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114–126.
14. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3:22–27.
15. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70:1–17.
16. Lambert D, Mourot J. Vitamin E and lipoproteins in hyperlipoproteinemia. Atherosclerosis. 1984;53:327–330.
17. Lamon-Fava S, Sadowski JA, Davidson KW, et al. Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am J Clin Nutr. 1998;67:1226–1231.
18. Gershkovich P, Hoffman A. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci. 2007;32:24–32.
19. International Organization for Standardization. ISO 15189 [web site]. 2012. Available at: https://www.iso.org/standard/561156.html. Accessed April 4, 2018.
20. Bennion BJ, Be NA, McNerney MW, et al. Predicting a drug’s membrane permeability: a computational model validated with in vitro permeability assay data. J Phys Chem B. 2017;121:5228–5237.
21. Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res.* 2006;34:D668–D672.

22. Steuer C, Huber AR, Bernasconi L. Where clinical chemistry meets medicinal chemistry. Systematic analysis of physico-chemical properties predicts stability of common used drugs in gel separator serum tubes. *Clin Chim Acta.* 2016;462:23–27.

23. Dos Santos Pereira JN, Tadjerpisheh S, Abu Abed M, et al. The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. *AAPS J.* 2014;16:1247–1258.

24. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. *Cell.* 2015;161:161–172.

25. Ma X, Song Q, Gao X. Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery. *Acta Pharm Sin B.* 2018;8:51–63.

26. Mahmoudian M, Salatin S, Khosroushahi AY. Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery. *Cancer Chemother Pharmacol.* 2018;82:371–382.